Hisamitsu Pharmaceutical Co., Inc.
HTSUY
Other OTC6.65
USD
- -
- -
ISIN
US43358N1072
Return %
Stock
S&P500
1Y
-1.48
26.53
3Y
4.07
76.60
5Y
-35.44
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kazuhide Nakatomi
- Full Time Employees
- 2,769
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 408 Tashirodaikan-machi Tosu Japan 841-0017
- IPO Date
- Sep 6, 2017
- Website
- hisamitsu.co.jp
- Similar Companies
- Business
- Hisamitsu Pharmaceutical Co., Inc. is a Japanese multinational pharmaceutical company primarily engaged in the development, manufacture, and sale of prescription and over-the-counter pharmaceutical products, with a strong emphasis on transdermal drug delivery system (TDDS) technologies. The company's core product portfolio includes external pain-relieving patches such as the globally recognized Salonpas brand, prescription transdermal analgesic anti-inflammatory drugs including Mohrus Tape and Mohrus PAP XR, as well as other pharmaceutical products like female hormone patches, asthma treatment patches, and overactive bladder treatment patches. Hisamitsu also offers quasi-drugs and cosmetics, and has expanded its product lines to include internal medicines, eyedrops, and skincare products like the Lifecella Face Mask. Founded in 1847 and established as a corporation in 1944, Hisamitsu maintains headquarters in Saga Prefecture and Tokyo, Japan, with global operations extending across Asia, North America, Europe, Brazil, and Africa. The company holds two subsidiaries in the United States: Hisamitsu America, Inc. and Noven Pharmaceuticals, with additional facilities dedicated to clinical research and product development. Hisamitsu’s products, especially Salonpas patches and related external analgesics, are marketed in over fifty countries, serving a broad customer base that includes both retail consumers and healthcare providers. Recent corporate developments include Hisamitsu's strategic investment in ReEir, Inc., a bio-venture focused on regenerative and cell medicine, signaling a push into advanced biomedical technologies. In 2024, the company initiated clinical development of HP-3150, a transdermal nonsteroidal pain treatment in the U.S., and strengthened its domestic and international distribution channels. Additionally, Hisamitsu launched Salonpas in Nigeria in April 2024, marking its entry into the African market and reflecting its global expansion strategy. The company also introduced an Employee Shareholding Incentive Plan (E-Ship®) and completed the construction of the new Saga Global Research Center to enhance research capabilities. Hisamitsu remains committed to innovation in topical analgesics and transdermal drug delivery, leveraging proprietary technologies to extend product efficacy and patient convenience. Its leading product, Salonpas, has consistently been recognized as the world’s top OTC topical analgesic patch brand. The company continues to diversify its portfolio with advanced formulations, combination therapies, and smart delivery devices, aiming to address a wide range of pain management and therapeutic needs globally. This strategic focus underpins Hisamitsu’s position in the pharmaceutical industry as a pioneer in transdermal therapeutics and pain relief solutions.